Cabenuva is a medicine used to treat HIV in people whose virus is already under control. It is given as two shots into the muscle by a healthcare provider every month or every two months, instead of daily pills. It works by blocking two different steps the virus needs to make copies of itself.
Every report comes from a Lived member, sent anonymously.
Have you tried Cabenuva (Cabotegravir / Rilpivirine) for HIV Infection?
Cabenuva is a long-acting HIV treatment given as two injections instead of daily pills. It pairs two antiretroviral medicines, cabotegravir and rilpivirine, and together they form a complete HIV regimen, so no other HIV medicines are needed while it is working as planned. It is approved for adults and for adolescents 12 and older who weigh at least 35 kg (about 77 pounds), and only as a switch. A person's HIV must already be well controlled on their current treatment, with a viral load below 50 copies per milliliter of blood (usually reported as undetectable), and they should have no history of a regimen failing and no known resistance to either drug. It is not used to start treatment in someone whose virus is not yet suppressed. People often consider it because taking pills every day is a burden, a reminder of their diagnosis, or hard to keep private.
HIV copies itself inside immune cells, and each of the two drugs blocks a different step in that process. Rilpivirine is a reverse transcriptase inhibitor: it stops the enzyme the virus uses to turn its genetic material into DNA. Cabotegravir is an integrase inhibitor: it stops a second enzyme from inserting that viral DNA into the cell's own DNA, a step the virus needs before it can make new copies. Blocking two steps at once keeps the virus suppressed and makes it harder for resistant virus to emerge. Both drugs are made as slow-release suspensions that sit in the muscle and seep into the bloodstream over weeks, which is why an injection can replace a month or two of pills. The flip side is that the drugs fade slowly, and traces can remain in the body for 12 months or longer after the last dose.
A health care provider gives both injections at the same visit, one of each drug, into the muscles of the buttocks on opposite sides or at least 2 cm apart. There are two schedules. On the monthly schedule, a first pair of larger starting injections is followed by smaller injections every month. On the every-2-month schedule, starting injections are given one month apart, then every two months. Visits can fall up to 7 days before or after the scheduled date. The person and their clinician choose the schedule together. Some people first take the two drugs as daily tablets, Vocabria (cabotegravir) and Edurant (rilpivirine), with a meal for about a month to check how they tolerate them before switching to injections; others go straight to injections, taking the first ones on the last day of their old regimen. Keeping appointments is the central requirement. Late or missed injections let drug levels drop, and the virus can return and become resistant to these drugs and related ones. If a visit will be missed by more than 7 days, contact the clinic in advance: daily Vocabria and Edurant tablets, or another full HIV regimen, can cover the gap until injections resume. Anyone who stops Cabenuva needs to start another complete HIV regimen within a month of the last monthly injection, or within two months of the last every-2-month injection.
Injection site reactions are the most common side effect, reported by most people in the trials: pain, tenderness, swelling, redness or itching where the shots went in. They are usually mild to moderate, last about three days on average, and few people stop treatment because of them. Some people also have a mild fever or flu-like feeling, tiredness, headache, muscle aches, nausea, trouble sleeping or dizziness, and modest weight gain is possible. Within minutes of the rilpivirine injection, fewer than 1 in 100 people have a reaction that can include shortness of breath, stomach cramps, flushing, sweating, numbness in the mouth, dizziness, or back or chest pain. These reactions have begun to ease within minutes, and the clinic watches for them after each visit. Any new rash is worth reporting to the care team. Rarely, these drugs cause a serious allergic reaction that can affect the skin and internal organs. Get medical care right away for a rash with fever, blisters, mouth sores, red or inflamed eyes, a swollen face, or a rash with feeling generally very unwell. Trouble breathing or swelling of the lips, tongue or mouth is an emergency: call 911. Liver problems are also possible, so contact the care team promptly about yellowing of the skin or eyes, dark urine, pale stools or pain under the right ribs. Low mood, mood swings or negative thoughts, including thoughts of suicide, have been reported, mostly in people with a history of depression, and should be raised with the care team promptly.
Some medicines speed up the breakdown of cabotegravir or rilpivirine enough that HIV can escape control, so they must not be used with Cabenuva. These include the seizure medicines carbamazepine, oxcarbazepine, phenobarbital and phenytoin; the rifamycin antibiotics used for tuberculosis (rifampin, rifabutin and rifapentine); dexamethasone, a steroid, beyond a single dose; and the herbal supplement St. John's wort. Macrolide antibiotics such as clarithromycin and erythromycin raise rilpivirine levels and can add to a risk of dangerous heart rhythm changes; azithromycin raises them less and is usually preferred when one is needed. People taking methadone may need their dose watched and adjusted. Because Cabenuva lingers, these interactions remain relevant for months after stopping, so every new prescription, over-the-counter medicine or supplement should be checked with a pharmacist or prescriber. Cabenuva is not used in people who have had an allergic reaction to either drug. Liver tests are recommended for everyone on Cabenuva, and people with existing liver disease may be more likely to have liver problems. Cabenuva does not treat hepatitis B, a viral liver infection that some daily HIV pills (those containing tenofovir) also keep under control. Hepatitis B status is checked before switching: people who have hepatitis B need a plan to keep it treated, because it can flare if that treatment stops, and people who are not immune are usually offered vaccination. There is limited information on Cabenuva in pregnancy. Long experience with rilpivirine tablets has not shown a higher rate of birth defects, but cabotegravir has not been studied in pregnant people. Because both drugs can stay in the body for a year or more, anyone who could become pregnant should discuss their plans before starting. If treatment continues during pregnancy, viral load is checked more closely, since rilpivirine levels can fall.
Starting Cabenuva changes the rhythm of HIV care from a daily habit to a series of clinic visits. Each visit includes two injections and a short wait of about 10 minutes afterward. Soreness at the injection sites is common for a few days after each visit. In trials, people who switched kept their virus suppressed about as well as those who stayed on daily pills, and many reported being more satisfied with treatment. Viral load tests continue as part of regular follow-up to confirm the virus stays suppressed. Treatment failure is uncommon, but when it happens on Cabenuva the virus often becomes resistant to rilpivirine, which can narrow future options, so dependable attendance matters more than with pills, where a single late dose is less consequential. Travel, schedule changes or a move are worth planning around with the clinic ahead of time. If Cabenuva stops being a good fit, people can return to daily pills on the timing described under Dosage & Administration.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Cabenuva (Cabotegravir / Rilpivirine), what you've noticed, or ask the community a question.